. The clinical reports to date suggest that a beneficial response may be expected in about 25% of cases where there has been either a failure of response or a loss of temporary response to oestrogens or androgens.
The most suitable progestin and the optimal relative proportion of oestrogen to progestin have yet to be worked out in the human. A previous pilot trial (Stoll, 1965) compared the effects of progestins alone at maximum tolerated doses, progestin-oestrogen combination as used in oral contraceptives, and progestins combined with relatively high doses of oestrogen.
The present report assesses the effect on female breast cancer of Lyndiol, a commercially available oral contraceptive containing lynoestrenol, a progestin of the 19-nor-steroid group, combined with the oestrogen mestranol. In all, 65 postmenopausal women with advanced breast cancer were given this drug combination. The therapeutic effects and side-effects of one tablet daily (the contraceptive dose) are compared with those of three and of six tablets daily. The effect of the progestin moiety alone is compared with that of the oestrogen moiety alone. The correlation is examined between the likelihood of a response to Lyndiol and a previous response to other hormones; also between the likelihood of a response to Lyndiol and the hormonal status of the patient, as reflected in the vaginal smear taken before treatment is begun.
Clinical Material and Results
All 65 patients were post-menopausal and the disease was beyond the control of local surgery or radiotherapy. Those selected for the trial had objective signs of progressing softtissue disease which could be measured, and also photographed, wherever possible. Simultaneous treatment of the part under observation was not permitted by any method except by local dressings. All patients who had been castrated either surgically or radiotherapeutically had been so treated at least six months previously. In the 22 cases where oestrogen or androgen therapy had been given previously it was at least two months since such therapy had been stopped. Treatment with Lyndiol was instituted only if the disease was progressing in activity.
Of the 65 patients in this trial 53 persisted with hormone therapy for two months or longer (Table I) . Those Table III . Almost complete macroscopic regression of softtissue tumour occurred in 9 of the 42 patients taking Lyndiol. It was seen in 3 of 11 patients on six tablets daily, 2 of 10 patients on three tablets daily, and in 4 of 21 patients on one to two tablets daily. There was similar regression in one of the seven cases on lynoestrenol alone, but in none of the four cases on mestranol alone. The earliest measurable regression of the tumour was usually between six and eight weeks after instituting therapy. The duration of regression was between three and ten months, the average being five months. Fig. 1 enlargement and recurrent metastatic nodules in the scar. She was given stilboestrol 15 mg. daily for three months with no benefit. By August 1964 the skin nodules were ulcerated, the supraclavicular nodes were enlarged, and an ulcerated tumour was present on the under surface of the opposite breast. She was given Lyndiol six tablets daily, and within three months the enlarged nodes had regressed and the ulcerating areas on the left chest wall and the right breast were healed (Fig. 2) . Treatment was continued for 10 months, but after this period new nodular metastases appeared in the chest wall (Fig. 3) . When Lyndiol was stopped there was a further regression of the " hormone withdrawal " type (Fig. 4) , and this has persisted to date, 21 months after starting Lyndiol. Her liver-function tests showed a persistent rise in enzyme levels during treatment (see later), although she felt no ill effects. (Stoll, 1966) , where a proportion of patients failing to respond to oestrogen showed a response when progestins were added.
Side-effects
In the patients receiving Lyndiol, severe side-effects such as vomiting, depression, and lassitude caused cessation of treat- ment after one or two weeks in 7 out of 54 cases. Other sideeffects included nausea, breast and pelvic discomfort, dizziness, constipation, and dyspepsia. " Breakthrough " uterine bleeding was noted in a few patients in the low-dosage group, but this was controlled by increasing the dosage to two tablets daily. Occasional patients receiving Lyndiol, lynoestrenol, or mestranol complained of nausea or vomiting while persisting with the drugs, but those symptoms could be in the main controlled by antiemetic drugs. There was no obvious difference in the proportion of these side-effects between patients on high and those on low dosage of Lyndiol.
Routine liver-function studies were carried out in all except the earliest cases in the series (Table IV) . In addition, liver biopsy was carried out in seven cases where the serum trallsaminase level was grossly raised. Some of the results have already been described (Stoll et al., 1965 (Stoll et al., , 1966 (Stoll et al., 1965 (Stoll et al., , 1966 (Stoll, 1965) . Such a correlation has not been established in the past for either oestrogen or androgen therapy.
The histological structure of the vaginal epithelium, both before and after the menopause, normally mirrors the endogenous ovarian and adrenal secretion, but can also be influenced by extraneous Finkbeiner, 1960) . In all the cases considered in this paper a vaginal smear to determine cytohormonal status was examined before treatment was started. This baseline smear was repeated more than once in some cases, because of fluctuations in oestrogen secretion said to occur after the menopause, but remarkably little variation was found. As stated above, in the case of patients who had received other forms of sex-hormone therapy previously, a therapy-free period of at least two months was insisted on before the patient entered this trial. This period of time allows the smear to return to the pre-therapeutic pattern in our experience, and our baseline figures are therefore not influenced by previous hormone therapy. This is evident also from study of Our observations in the past (Stoll, 1966) slightly at first, more so with higher dosage, but reverts to zero after four to eight weeks in practically all cases even while therapy continues.
Discussion
As noted in the introduction, the clinical use of combined progestin and oestrogen therapy in breast cancer is based upon carefully established experimental observations in animals. Clinically it is well known that oophorectomy, adrenalectomy, hypophysectomy, and androgen administration are often capable of causing regression in the growth of female breast cancer. Huggins et al. (1962) reported a hormone-sensitive spontaneous mammary cancer in female rats which will also regress after castration, adrenalectomy, hypophysectomy, and androgen administration. As this tumour can be induced at will by dimethylbenzanthracene-feeding, it is a most useful experimental model for obtaining information on the response of hormone-sensitive mammary cancer to other methods of hormonal regulation. Huggins et al. (1962) reported that the addition of small doses (20 ,ug. daily) of oestradiol to large doses (4 mg. daily) of progesterone is capable of completely extinguishing tumour growth in these animals in over half the cases. They emphasized that the relative doses of progesterone and oestrogen are important, but in a later clinical report (Landau et al., 1962) Lyndiol at a dose of one to six tablets daily brought a clinical remission in 9 out of 42 patients when the drug was continued for two months or more. The smallest dose (the contraceptive dose) seems to produce a similar response to the larger dose, with the advantage of a much smaller incidence of liver damage, as judged by S.G.O.T. levels. The progestin component given alone caused a remission in one of the seven cases investigated. The oestrogen component given alone brought no remission in the four cases treated. This would suggest possible synergism between the components (as noted by Huggins in experimental animals), but these findings are not statistically significant.
The mode of action of such a progestin-oestrogen combination in the control of breast cancer growth is speculative. The oestrogen-dependent theory to explain hormonal control in breast cancer is outmoded, and it has been suggested that, once established, the tumour is pituitary-dependent. Oestrogen therapy and androgen therapy probably suppress the prolaetin or gonadotrophin (luteinizing and/or follicle-stimulating hormone) secretion of the anterior pituitary (Stoll, 1958) . The observation that oral contraceptives decrease the urinary excretion of luteinizing hormone (Brown et al., 1964) suggests that these agents act as contraceptives by suppressing the synthesis or the release of pituitary luteinizing hormone (Diczfalusy, 1965) . Their action in breast cancer may be similar.
It is essential that the incidence of breast and genital cancer developing in women receiving oestrogens and progestins be studied intensively. This applies more particularly now, because of the widespread use of oral contraceptives. If an analogy with experimental mammary cancer is permissible, then the incidence of breast cancer developing in pre-menopausal women may be reduced (Stoll, 1965) . This present report, based as it is upon the treatment of post-menopausal females, provides no relevant information in this respect. However, this report supports the suggestion that the use of oestrogen-progestin mixtures, after the menopause, may well reduce the rate of development of breast cancer in some women (Wilson, 1962 Gootman et al. (1964) reported thrombosis of the pulmonary arteries occurring in two patients with nephrosis who were treated with prednisone and chlorothiazide. This is the first time that such an association has been found. Subsequently, on reviewing 75 cases of primary renal disease in children, Symchych and Perrin (1965) found three instances of this association in children who had been treated with corticosteroids. We wish to record a further example of a child with the nephrotic syndrome who died as a result of extensive thrombosis of the pulmonary arteries while receiving corticosteroids and spironolactone.
CASE REPORT
A Bantu boy aged 3 years 9 months was admitted to hospital on 31 March 1964 with a history of swelling of the body and face, cough, and anorexia of two weeks' duration.
On examination his temperature was 1010 F. (38.30 C.), pulse 140, and body weight 301 lb. (13.8 kg.). There was oedema of the trunk, face, scrotum, and limbs. The blood pressure was 100/60 mm. Hg. A purulent nasal discharge was present. There was dullness to percussion with diminished air entry at both lung bases, and this was ascribed to the presence of pleural effusions. The liver was just palpable, and there was ascites. A specimen of urine contained albumin (+ +), hyaline and granular casts, and 18 white cells per high-power microscopical field. A clinical diagnosis of the nephrotic syndrome was made.
Investigations.-An electrocardiogram was within normal limits. The Mantoux test was negative; haemoglobin 11.5 g./100 ml.; leucocyte count 8,200/cu. mm. (normal differential count); platelets adequate and the sedimentation rate (Wintrobe) 48 mm. in one hour; total serum proteins 4 g./100 ml. (albumin 0.9 g., globulin 3.1 g.); serum cholesterol 440 mg./lQO ml. A nasal swab was negative for Corynebacterium diphtheriae, and a rectal swab showed no pathogens. The blood urea and serum electrolyte levels were within normal limits. Intravenous pyelogram was normal. The protein content in the urine throughout his stay in hospital was assessed by Esbach's method.
The child was kept in bed without treatment for the first week. During this time his weight rose and the albuminuria persisted. Prednisone by mouth was started on 7 April in a dose of 10 mg. every eight hours (30 mg./day). A satisfactory diuresis occurred,
